Patents Assigned to Genentech
  • IMMUNO-PET IMAGING OF ANTIBODIES AND IMMUNOCONJUGATES AND USES THEREFOR
    Publication number: 20170121424
    Abstract: Anti-STEAP-1 antibodies and immunoconjugates thereof are provided. Methods of using anti-STEAP-1 antibodies and immunoconjugates thereof are provided. Methods of detecting or determining the presence of STEAP-1 proteins are provided.
    Type: Application
    Filed: October 10, 2016
    Publication date: May 4, 2017
    Applicant: Genentech, Inc.
    Inventors: Mark DENNIS, Jan MARIK, Paul POLAKIS, Bonnee RUBINFELD, Simon WILLIAMS
  • Production of heteromultimeric proteins
    Patent number: 9637557
    Abstract: Described herein are methods for the efficient production of antibodies and other multimeric protein complexes (collectively referred to herein as heteromultimeric proteins) capable of specifically binding to more than one target. The targets may be, for example, different epitopes on a single molecule or located on different molecules. The methods combine efficient, high gene expression level, appropriate assembly, and ease of purification for the heteromultimeric proteins. The invention also provides methods of using these heteromultimeric proteins, and compositions, kits and articles of manufacture comprising these antibodies.
    Type: Grant
    Filed: April 22, 2011
    Date of Patent: May 2, 2017
    Assignee: Genentech, Inc.
    Inventors: Justin Scheer, Christoph Spiess, Daniel G. Yansura
  • METHODS OF TREATING CANCER USING PD-1 AXIS BINDING ANTAGONISTS AND MEK INHIBITORS
    Publication number: 20170112925
    Abstract: The present invention describes combination treatment comprising a PD-1 axis binding antagonist and a MEK inhibitor and methods for use thereof, including methods of treating conditions where enhanced immunogenicity is desired such as increasing tumor immunogenicity for the treatment of cancer.
    Type: Application
    Filed: January 5, 2017
    Publication date: April 27, 2017
    Applicant: Genentech, Inc.
    Inventor: Melissa JUNTTILA
  • INFLUENZA A H7N9 VIRUS THERAPIES
    Publication number: 20170114121
    Abstract: The present invention provides anti-influenza A virus antibodies effective at binding, neutralizing, and treating influenza A H7N9 virus, compositions comprising such antibodies, and methods of using the same.
    Type: Application
    Filed: July 21, 2016
    Publication date: April 27, 2017
    Applicant: Genentech, Inc.
    Inventors: Ning Chai, Jacqueline McBride, Lee Swem
  • Genetic variations associated with tumors
    Patent number: 9631240
    Abstract: Nucleotide and amino acid variations associated with tumors are provided. Methods for detecting variations and for diagnosing and treating tumors are provided.
    Type: Grant
    Filed: March 6, 2014
    Date of Patent: April 25, 2017
    Assignee: Genentech, Inc.
    Inventors: Zhengyan Kan, Denise M. Kenski, Brock Peters, Somasekar Seshagiri
  • Compositions and methods for prostate cancer analysis
    Patent number: 9632091
    Abstract: The invention provides methods for diagnosing prostate cancer. The invention also provides novel anti-STEAP-1 antibodies and uses thereof.
    Type: Grant
    Filed: October 21, 2015
    Date of Patent: April 25, 2017
    Assignee: GENENTECH, INC.
    Inventors: Siminder Atwal, Jo-Anne Hongo, Mark Lackner, Elizabeth Punnoose, Bonnee Rubinfeld, Rajesh Vij
  • Method for preparing a composition comprising highly concentrated antibodies by ultrafiltration
    Patent number: 9630988
    Abstract: The present invention provides a method for preparing a composition comprising highly concentrated antibodies by ultrafiltration in batch concentration mode having a first constant feed rate step and a second controlled feed rate step.
    Type: Grant
    Filed: August 31, 2012
    Date of Patent: April 25, 2017
    Assignees: Chugai Seiyaku Kabushiki Kaisha, Genentech, Inc.
    Inventors: Kelby Lau, Jean Bender, Saeko Tanaka, Rumiko Wakayama, Hidenari Yamada, Tomonori Isoda, Masayoshi Oh-Eda
  • METHODS AND COMPOSITIONS FOR MODULATING HGF/MET
    Publication number: 20170106042
    Abstract: The invention provides methods and compositions for modulating the HGF/c-met signaling pathway, in particular by regulating binding of HGF ? chain to c-met.
    Type: Application
    Filed: May 23, 2016
    Publication date: April 20, 2017
    Applicant: Genentech, Inc.
    Inventors: Daniel K. Kirchhofer, Robert A. Lazarus, Xiaoyi Yao
  • METHODS OF USING ANTI-PD-L1 ANTIBODIES AND THEIR USE TO ENHANCE T-CELL FUNCTION TO TREAT TUMOR IMMUNITY
    Publication number: 20170107287
    Abstract: The present application relates to anti-PD-L1 antibodies, nucleic acid encoding the same, therapeutic compositions thereof, and their use enhance T-cell function to upregulate cell-mediated immune responses and for the treatment of T cell dysfunctional disorders, including infection (e.g., acute and chronic) and tumor immunity.
    Type: Application
    Filed: October 26, 2016
    Publication date: April 20, 2017
    Applicant: Genentech, Inc.
    Inventors: Bryan IRVING, Henry CHIU, Heather MAECKER, Sanjeev MARIATHASAN, Sophie M. LEHAR, Yan WU, Jeanne CHEUNG
  • Peptide inhibitors of BACE1
    Patent number: 9624269
    Abstract: The invention provides peptide inhibitors of BACE1 that bind to the active site in a noncanonical fashion, and methods of use thereof.
    Type: Grant
    Filed: November 20, 2015
    Date of Patent: April 18, 2017
    Assignee: Genentech, Inc.
    Inventors: Robert A. Lazarus, Yingnan Zhang, Weiru Wang
  • USE OF BIOMARKERS FOR ASSESSING TREATMENT OF GASTROINTESTINAL INFLAMMATORY DISORDERS WITH BETA7 INTEGRIN ANTAGONISTS
    Publication number: 20170102393
    Abstract: The present invention is directed to methods of using biomarkers to assess treatment of gastrointestinal inflammatory disorders with beta7 antagonists. More particularly, the present invention relates to methods of using the level of gut-homing lymphocytes in peripheral blood, the level of drug occupancy on gut-homing lymphocytes, and/or the level of beta7 integrin receptors on gut-homing lymphocytes as indicators (or biomarkers) of the effect, efficacy, safety, prognosis, and/or dosing of therapeutic agents, such as beta7 integrin antagonists, for the treatment of gastrointestinal inflammatory disorders.
    Type: Application
    Filed: May 6, 2016
    Publication date: April 13, 2017
    Applicant: GENENTECH, INC.
    Inventors: Thomas Richard Gelzleichter, Hajime Hiraragi, Eric Gary Stefanich, Hong Wang, Marna Bromberg Williams
  • ANTI-ANGIOGENESIS THERAPY FOR THE TREATMENT OF BREAST CANCER
    Publication number: 20170100478
    Abstract: This invention concerns in general treatment of diseases and pathological conditions with anti-VEGF antibodies. More specifically, the invention concerns the treatment of human subjects susceptible to or diagnosed with breast cancer using an anti-VEGF antibody, preferably in combination with one or more additional anti-tumor therapeutic agents.
    Type: Application
    Filed: December 20, 2016
    Publication date: April 13, 2017
    Applicant: Genentech, Inc.
    Inventors: Gwendolyn Fyfe, See Chun Phan, Xian Zhou
  • PROCESS FOR THE PREPARATION OF (E)-3-(4-((E)-2-(2-CHLORO-4-FLUOROPHENYL)-1-(1H-INDAZOL-5-YL)BUT-1-EN-1-YL)PHENYL)ACRYLIC ACID
    Publication number: 20170101380
    Abstract: Processes are described for the preparation of estrogen receptor modulating compound, (E)-3-(4-((E)-2-(2-chloro-4-fluorophenyl)-1-(1H-indazol-5-yl)but-1-en-1-yl)phenyl)acrylic acid I: and salts thereof, and intermediates useful for the preparation of I.
    Type: Application
    Filed: October 6, 2016
    Publication date: April 13, 2017
    Applicant: Genentech, Inc.
    Inventors: Stephan Bachmann, Serena Maria Fantasia, Francis Gosselin, Chong Han, Stefan Hildbrand, Theresa Humphries, Christian Jenny, Ngiap-Kie Lim, Andrew McClory, Christian Moessner, Pankaj Rege, Scott Savage, Haiming Zhang
  • Methods for assessing responsiveness of B-cell lymphoma to treatment with anti-CD40 antibodies
    Patent number: 9617600
    Abstract: The invention provides methods and kits useful for predicting or assessing responsiveness of a patient having B-cell lymphoma to treatment with anti-CD40 antibodies.
    Type: Grant
    Filed: April 17, 2010
    Date of Patent: April 11, 2017
    Assignee: Genentech, Inc.
    Inventors: David Dornan, Bart Burington
  • ANTIBODY VARIANTS
    Publication number: 20170096480
    Abstract: Antibody variants of parent antibodies are disclosed which have one or more amino acids inserted in a hypervariable region of the parent antibody and a binding affinity for a target antigen which is at least about two fold stronger than the binding affinity of the parent antibody for the antigen.
    Type: Application
    Filed: December 20, 2016
    Publication date: April 6, 2017
    Applicant: Genentech, Inc.
    Inventors: Yvonne M. Chen, Henry B. Lowman, Yves Muller
  • PYRROLOBENZODIAZEPINE ANTIBODY DRUG CONJUGATES AND METHODS OF USE
    Publication number: 20170095570
    Abstract: The invention provides antibody-drug conjugates comprising an antibody conjugated to a pyrrolobenzodiazepine drug moiety via a disulfide linker, pyrrolobenzodiazepine linker-drug intermediates, and methods of using the antibody-drug conjugates.
    Type: Application
    Filed: September 30, 2016
    Publication date: April 6, 2017
    Applicant: Genentech, Inc.
    Inventors: Peter Dragovich, Thomas Pillow, Jack Sadowsky, Mark X. Sliwkowski, BinQing Wei
  • Combinations of AKT inhibitor compounds and erlotinib, and methods of use
    Patent number: 9610289
    Abstract: The invention provides A combination of, a) a compound of Formula Ia: or a pharmaceutically acceptable salt thereof; and b) erlotinib or a pharmaceutically acceptable salt thereof for the prophylactic or therapeutic treatment of a hyperproliferative disorder, such as cancer.
    Type: Grant
    Filed: August 26, 2015
    Date of Patent: April 4, 2017
    Assignee: GENENTECH, INC.
    Inventors: Michelle Nannini, Deepak Sampath
  • Low affinity blood brain barrier receptor antibodies and uses therefor
    Patent number: 9611323
    Abstract: The present invention relates to antibodies that bind blood brain barrier receptors (BBB-R) and methods of using the same.
    Type: Grant
    Filed: December 19, 2014
    Date of Patent: April 4, 2017
    Assignee: Genentech, Inc.
    Inventors: Mark Dennis, Ryan Jefferson Watts, Yunhua Joy Yu, Yin Zhang
  • MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS
    Publication number: 20170088582
    Abstract: Provided herein are antibacterial compounds, wherein the compounds in some embodiments have broad spectrum bioactivity. In various embodiments, the compounds act by inhibition of bacterial type 1 signal peptidase (SpsB), an essential protein in bacteria. Pharmaceutical compositions and methods for treatment using the compounds described herein are also provided.
    Type: Application
    Filed: May 19, 2015
    Publication date: March 30, 2017
    Applicants: RQX PHARMACEUTICALS, INC., GENENTECH, INC.
    Inventors: Tucker Curran ROBERTS, Peter Andrew SMITH, Robert I. HIGUCHI, Prasuna PARASELLI, Philippe BERGERON, Michael F.T. KOEHLER, Huiyong HU, Jacob Bradley SCHWARZ, Cuong LY, James CRAWFORD
  • 3-SUBSTITUTED PYRAZOLES AND USES THEREOF
    Publication number: 20170087137
    Abstract: The present invention provides for compounds of Formula (I) and various embodiments thereof, and compositions comprising compounds of Formula (I) and various embodiments thereof. In compounds of Formula I, the groups R1, R2, R3, R4, R5, R6 and R7 have the meaning as described herein. The present invention also provides for methods of using compounds of Formula I and compositions comprising compounds of Formula (I) as DLK inhibitors and for treating neurodegeneration diseases and disorders.
    Type: Application
    Filed: December 9, 2016
    Publication date: March 30, 2017
    Applicant: Genentech, Inc.
    Inventors: Anthony Estrada, Wen Liu, Snahel Patel, Michael Siu